Latest Breaking News On - Novartis strategy financial communications - Page 3 : comparemela.com

Novartis Pharma AG: Novartis appoints Rob Kowalski as Chief People & Organization Officer

Novartis Pharma AG: Novartis appoints Rob Kowalski as Chief People & Organization Officer Basel, June 28, 2021 - Novartis announced today the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective September 1, 2021. Steven Baert, currently Chief People & Organization Officer, will step down from the Executive Committee of Novartis, effective June 30, 2021 after 15 years with the company and almost 8 years in position. Vicki Rawlinson, US Head People & Organization will lead the function ad-interim until Dr. Kowalski takes over.

United statesRichard jarvisIsabella zinckThomas hungerbuehlerSamir shahJulie masowVicki rawlinsonSloan simpsonRob kowalskiSteven baertPeople organizationGlobal head regulatory affairsNovartis drug developmentUs head people organizationNovartis strategy financial communicationsBachelor of pharmaceutical sciences

Novartis AG (via Public) / Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland (Form 6-K)

Novartis AG (via Public) / Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland (Form 6-K)
publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.

United statesRichard jarvisIsabella zinckThomas hungerbuehlerSamir shahJulie masowVicki rawlinsonSloan simpsonRob kowalskiSteven baertPeople organizationGlobal head regulatory affairsUs head people organizationNovartis strategy financial communicationsUs head of drug developmentNovartis global communications

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

NOVARTIS AG CHF0.50(REGD) Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177 Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary New Kisqali (ribociclib) overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer Phase II results for oral, targeted factor B inhibitor iptacopan (LNP023) as

United statesIsabella zinckSamir shahJulie masowThomas hungerbuehlerSloan simpsonSusanne schaffertFiona phillipsAmerican society of clinical oncologyNovartis institutes for biomedical researchAstex pharmaceuticalsEuropean hematology associationNovartis strategy financial communicationsNovartis oncology communicationsNovartis us external communicationsExchange commission

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesIsabella zinckSamir shahJulie masowThomas hungerbuehlerSloan simpsonSusanne schaffertFiona phillipsAmerican society of clinical oncologyNovartis institutes for biomedical researchAstex pharmaceuticalsEuropean hematology associationNovartis strategy financial communicationsNovartis oncology communicationsNovartis us external communicationsExchange commission

Novartis Pharma AG: Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

Novartis Pharma AG: Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.